Valeriana officinalis has been extensively used as a herbal remedy in traditional medicine. However, there is no clear evidence on the antinociceptive effects of this plant. The aim of our study was to evaluate the effect of Valeriana officinalis hydroalcoholic extract on pain modulation and its possible mechanism in mice. Adult male Balb/c mice were randomly divided into nine experimental groups. They received i.p. injections of saline, hydroalcoholic root extract of Valeriana officinalis (800, 200, or 50 mg/kg), and morphine; four groups received Valeriana (800 mg/kg) + antagonists of the systems involved in antinociception effects, naloxone, ondansetron, metoclopramide, or scopolamine. Tail-flick and writhing tests were used for estimation of possible modulation of pain. The tail-flick latencies in the Valeriana 800 and 200 mg/kg, but not 50 mg/kg, morphine, and combined Valeriana 800 + + naloxone, ondansetron, metoclopramide, or scopolamine-treated groups were significantly longer than that in the control group. However, the tail-flick latencies in the Valeriana 800 mg/kg + ondansetronand metoclopramide-treated groups were significantly shorter than that upon single action of the extract (800 mg/kg). The numbers of writhings in the extract-treated groups were smaller than in the control one. The numbers of writhings in the Valeriana (800 mg/kg)+ ondansetron-and metoclopramidetreated groups were significantly greater than in the extract (800 mg/kg) group. It is concluded that Valeriana officinalis extract possesses a clear analgesic effect and works through the serotonergic and dopaminergic systems.
INTRODUCTION
In recent years, there has been significant scientific progress in the neurobiology of pain control and introduction of the respective modern technologies. Nonetheless, we still need new analgesic drugs with better efficacy and lesser side effects. There are several approaches allowing us to use metabolites and compounds derived from known and novel plants to make these drugs [1] .
Valeriana officinalis is a well-known plant growing wild in America and Eurasia [2] and commonly used in traditional medicine [3] . According to many studies, Valeriana possesses sedative, anxiolytic, tranquilizing, spasmolytic, and anticonvulsant effects [4] [5] [6] [7] [8] . The practical lack of side effects and low price are features that make Valeriana so common [9] . Valeriana , when producing hypolocomotor and axiolytic-like effects in rats, did not alter oxidative stress parameters in the CNS, liver, and kidneys [10] .
Alkaloids, lignan, flavonoids, GABA, and valerenic acid are active compounds found in Valeriana officinalis extracts [6, 11, 12] . According to a few investigations, flavonoids exert antinociceptic effects, and Valeriana alkaloids are also members of the analgesic complement family [1, 13, 14] . As we see, Valeriana has a number of positive effects on the nervous system, but there are no direct studies related to possible antinociceptive effects of this remedy. The aim of our study was to estimate the analgesic activity of different doses of the extract from this plant and also to discover possible mechanisms underlying its action.
METHODS
Animals. Adult male Balb/c mice weighing 25-35 g were obtained from the Iran Pasteur Institute, Tehran. They were kept at a constant temperature of 22 ± 2°C with a 12/12-h light/dark cycle (lights on at 7:00 a.m). Food and water were available ad libitum in the home cages. The animals were acclimated to the environment for 1 week before the experimental procedure. All procedures and experiments were performed between 10:00 and 14:00.
Herbal Material and Extraction. Dried roots of Valeriana officinalis were purchased from the Herbal Medicine Research Center in Hamadan, Iran. The ground material was immersed in 70% ethanol for 72 h at room temperature. The extract was filtered and then freezer-dried.
Tail-Flick Test. A tail-flick apparatus for mice was used to produce radiant heat on the mouse tail (about 3 cm from the tip). The heat intensity was adjusted such that the mean tail-flick latency (TFL) was about 3 sec, and a maximum cut-off time of 8 sec was set to avoid tissue damage. Mice were randomly divided into nine groups (n = 8 each). These groups received saline (control group), dry Valeriana extract (800, 200, or 50 mg/kg) dissolved in saline, morphine (1 mg/kg; positive antinociception control group), and co-administrations of Valeriana (800 mg/kg) with naloxone (a blocker of opioid receptors, 4 mg/kg), ondansetron (an antagonist of the serotonergic system, 0.5 mg/kg), metoclopramide (an antagonist of the dopaminergic system, 1 mg/kg), or scopolamine (an antagonist of muscarinic cholinoreceptors, 1 mg/kg). Three tailflick trials (with 1-min-long intertrial intervals) were performed before and after drug administration. The TLF for each rat was calculated as the average of three consecutive measurements.
Acetic Acid Writhing Test. This test is based on chemical induction of visceral pain. Acetic acid (0.6% in saline, 0.1 ml/10 g body mass) was administered by i.p injections. Immediately after administration, each animal was placed inside a transparent Plexiglas box. The number of abdominal writhes accompanied by elongation of the body and stretching of the hindlimbs was counted for 30 min. The experimental groups (n = 8 each) were treated similarly to what was described for the tail-flick test.
Statistical Analysis. The Student's paired t-test was used for comparing the baseline and postinjection TLFs. Statistical comparisons among experimental groups were performed by one-way analysis of variance (ANOVA) followed by the Tukey test. The level of P < 0.05 was taken as significant. Data are presented below as means ± s.e.m. extract at doses of 200 and 800 mg/kg (but not of 50 mg/kg), morphine, and Valeriana (800 mg/kg) with naloxone, ondansetron, metoclopramide, and scopolamine significantly increased the TFL, as compared with the pretreatment (Fig. 1) . Comparison of the TFL using one-way ANOVA indicated that there were no significant differences between the experimental groups before treatment (P > 0.05), but the differences were highly significant after treatment (P < 0.0001). The Tukey post-hoc test showed that the TFL values showed no significant difference between the Valeriana (800 mg/kg) and morphine groups, Valeriana (800 mg/kg) + naloxone, and Valeriana (800 mg/kg) + + scopolamine. However, the TFL mean value in the Valeriana (800 mg/kg) group was significantly greater than TFLs in the groups that received 200 and 50 mg/kg of the Valeriana extract, Valeriana (800 mg/kg) + ondansetron, and Valeriana (800 mg/kg)+ metoclopramide (Fig. 1) .
RESULTS

Tail
Writhing Test. Statistical analysis by oneway ANOVA showed that there were significant differences in the number of writhings between animal groups (P < 0.0001). The Tukey posthoc test indicated that, except for the Valeriana (50 mg/kg) group, the numbers of writhings in other groups were significantly smaller than those in the control group. Also, there were no significant differences in the number of writhings between the mouse groups treated with Valeriana (800 mg/kg), Valeriana (800 mg/kg) + naloxone, and Valeriana (800mg/kg) + scopolamine. However, the mean numbers of writhings in the two Valeriana-treated groups (50 and 200 mg/kg), 800 mg/kg Valeriana + ondansetron, and 800 mg/kg Valeriana + metoclopramide were significantly greater than those in mice that received only 800 mg/kg Valeriana (Fig. 2) .
DISCUSSION
Progress in developing analgesic drugs has been rather significant in recent years, but the need for drugs with better effects remains. Herbal medicine and the use of medicinal plants is one of the main ways to meet this need, and more and more investigations are performed in this field.
Valeriana ofiicinalis in Eurasia and America, Valeriana wallichi in India, and Valeriana angustifolia in China and Japan are species of Valeriana that are extensively used for calming, sleep induction, and sedative effects in different nations. Valeriana decreases the general activity of the CNS via inhibiting GABA breakdown in particular [9, 12, 15, 16] . Valeriana is also used for relieving anxiety and for insomnia [17] [18] [19] .
To our knowledge, the analgesic effects of this plant have not been estimated directly until now. Results of our study show that the hydroalcoholic extract of Valeriana officinalis demonstrates significant dose-dependent antinociceptive effects. The highest (800 mg/kg) dose of the extract successfully reduced somatic pain, while a 50 mg/kg dose did not. Ondansetron, a serotonergic system antagonist, and metoclopramide, a dopaminergic system antagonist, significantly decreased the effect of the extract, showing that Valeriana blocked pain via its influence on the respective pathways. We can say that ondansetron exerted a more intense blocking effect compared to that of metoclopramide. We found no significant difference between the animal groups treated with Valeriana (800 mg/kg), Valeriana (800 mg/kg) + naloxone, and Valeriana (800 mg/kg) + + scopolamine, indicating that the antinociception effect of the extract is preserved, and that the opioidergic and cholinergic systems are probably not involved so significantly in the induction of antinociceptic effects of the Valeriana extract. The antinociceptive activity was also clearly expressed as significant reduction in the number of abdominal writhings when compared to that in control animals. In this test, we obtained results comparable with those in the tail-flick test. The numbers if withings were reduced with increase in the dose of the extract; thus, the dose dependence of the Valeriana hydroalcoholic extract was also quite clear. In this test, ondansetron and metoclopramide also antagonized the effects of the extract.
Valeriana may affect the CNS by interaction with the serotonin, GABA, melatonin, or adenosine systems [20] . Long-term treatment with Valeraiana officinalis exerted no effect on the reduction of dopamine uptake in the striatum of Wistar rats [10] . Aqueous and methanolic extracts of Valeriana adscendens (one of the Valeriana species) showed affinity with respect to D 1 and 5-HT 1A receptors, while no affinity with respect to noradrenergic receptors has been reported [21] . 6-Methylapigenin is a flavonoid detected in Valeriana officinalis. This flavone is a ligand for a benzodiazepine binding site in GABA A receptors and was reported to cause anxiolytic effects in mice [22] . A flavonoid, 1-hydroxypinoresinol, derived from Valeriana officinalis, is a ligand for 5-HT 1A receptors [23] ; these receptors were found to be involved, with high efficacy, in the central analgesia mechanism [24, 25] . Hesperidin, a flavonone glycoside, was found to be present in Valeriana [11] , and it was reported that linarin, another flavonone glycoside, was also found in this plant [26] . Clear sedation [27] and antinociception [28] effects of hesperidin have been reported earlier.
Thus, the antinociception effects of Valeriana officinalis have been assessed quite obviously. These effects are significantly antagonized by ondansetron and metoclopramide. Naloxone and scopolamine exerted much smaller influences on the Valeriana hypoalgezic effects in the tailflick and writhing tests. We can conclude that the antinociception effects of this remedy are mediated by the serotonergic and dopaminergic systems, and flavonoids affect the latter. These pathways have not been reported for the Valeriana officinalis effects earlier, and our results may serve as a motivation for further investigations in this field.
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